Epithelioid Sarcoma Market to Expand at a Significant Growth Rate During the Forecast Period (2019-32) - Estimates DelveInsight

As per DelveInsight, the Epithelioid Sarcoma Market is anticipated to evolve immensely in the coming years owing to the expected launch of emerging therapies and the rise in the number of cases. The emerging pipeline for the treatment of Epithelioid Sarcoma is not robust. Very few candidates are being investigated by pharmaceutical companies in this disease area.

DelveInsight's "Epithelioid Sarcoma Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Epithelioid Sarcoma Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Epithelioid Sarcoma market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Epithelioid Sarcoma: An Overview
Epithelioid sarcoma (ES) is one of the common STSs types. Epithelioid sarcoma is a rare soft tissue sarcoma in young adults (20-39-year-olds) involving the upper extremities 60% of the time. The name was given by Enzinger in 1970 to a group of soft tissue sarcomas that were confused with a variety of malignant and benign conditions, especially granulomatous process, synovial sarcoma, and ulcerating squamous cell carcinoma.

ES is a slow-growing type of soft tissue cancer. Most cases begin in the soft tissue under the skin of a finger, hand, forearm, and lower leg or foot, though it can start in other areas of the body. Typically, ES starts as a small firm growth or lump that's painless. It usually starts out as a single growth, but multiple growths may occur by the time a person seeks medical help. Sometimes this sarcoma appears as ulcers that do not heal, looking like open wounds over the growths.

Epithelioid Sarcoma Market Key Facts
• As per the estimation of DelveInsight, there were 68 cases of ES in 2021, in the US, which was 37% of overall cases of 7MM.
• In 2021, among EU-5, Germany reported the highest cases of ES (24 cases), followed by Italy (21 cases) and France (20). The least cases were reported in Spain (13 cases).
• In the assessment of DelveInsight, it is found that 11% of overall cases of ES in 7MM were reported in Japan.
• In a study by Elsamna et al. (2019), 998 and 992 cases of ES were identified from the database and literature, respectively. Out of identified cases, the overall recurrence and metastasis rates were 63.4% and 40.3%.
• Epithelioid sarcoma (ES) is a rare sarcoma subtype, with an incidence rate of 0.02 per 100,000 and 0.05 per 100,000 in Europe and the United States, respectively.
• According to Needs et al. (2022), Epithelioid sarcomas are rare, representing less than 1% of soft tissue sarcomas, and have a predilection for men (up to 2:1 male to female ratio). Most reported tumors occur in young males ranging in age from 10 to 45 years. The extremes of ages include ages 4 to 90, with a median age of 27 years.

Epithelioid Sarcoma Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Epithelioid Sarcoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Epithelioid Sarcoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Epithelioid Sarcoma Market will Grow by 2032:
https://www.delveinsight.com/report-store/epithelioid-sarcoma-market?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=rpr

Epithelioid Sarcoma Epidemiology
The epidemiology section covers detailed insights into the historical and current Epithelioid Sarcoma patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Epithelioid Sarcoma Epidemiology Segmented as -
• Total Incident Cases of Soft-tissue sarcoma (STS) in the 7MM (2019 to 2032)
• Incident Cases of Epithelioid Sarcoma in the 7MM (2019 to 2032)
• Age-specific Incident Cases of Epithelioid Sarcoma in the 7MM (2019 to 2032)
• Gender-specific Incident Cases of Epithelioid Sarcoma in the 7MM (2019 to 2032)
• Stage-specific Incident cases of Epithelioid Sarcoma in the 7MM (2019 to 2032)
• Treatable Cases of Epithelioid Sarcoma in the 7MM (2019 to 2032)

Get Key Insights Into the Evolving Epithelioid Sarcoma Epidemiology Trends:
https://www.delveinsight.com/report-store/epithelioid-sarcoma-market?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=rpr

Epithelioid Sarcoma Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epithelioid Sarcoma market or expected to be launched during the study period. The analysis covers Epithelioid Sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Epithelioid Sarcoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/epithelioid-sarcoma-market?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=rpr

Epithelioid Sarcoma Therapeutics Assessment
The dynamics of the Epithelioid Sarcoma market are anticipated to change in the coming years due to the rise in healthcare spending worldwide. Key players, such as Epizyme, Inc. already is in the market for the treatment of Epithelioid Sarcoma, and now the company is further exploring the potential of molecules in combination.

Epithelioid Sarcoma Emerging Therapies
Tazemetostat in Combination With Doxorubicin is being investigated by Epizyme, Inc. In the study, Tazemetostat (800 mg) is administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycle 7 and beyond, whereas Doxorubicin is administered by IV on day 1 of cycles 1-6.

Learn More About the Emerging Therapies & Key Companies in the Epithelioid Sarcoma Therapeutics Market:
https://www.delveinsight.com/sample-request/epithelioid-sarcoma-market?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Epithelioid Sarcoma Competitive Intelligence Analysis
4. Epithelioid Sarcoma Market Overview at a Glance
5. Epithelioid Sarcoma Background and Overview
6. Epithelioid Sarcoma Patient Journey
7. Epithelioid Sarcoma Epidemiology and Patient Population
8. Epithelioid Sarcoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Epithelioid Sarcoma Unmet Needs
10. Key Endpoints of Epithelioid Sarcoma Treatment
11. Epithelioid Sarcoma Marketed Products
12. Epithelioid Sarcoma Emerging Therapies
13. Epithelioid Sarcoma Seven Major Market Analysis
14. Attribute Analysis
15. Epithelioid Sarcoma Market Outlook (7 major markets)
16. Epithelioid Sarcoma Access and Reimbursement Overview
17. KOL Views on the Epithelioid Sarcoma Market.
18. Epithelioid Sarcoma Market Drivers
19. Epithelioid Sarcoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/epithelioid-sarcoma-market?utm_source=digitaljournal&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.